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evelopment of a recombinant antigen and multiplex PCR
or differentiation of tick-borne and mosquito-borne ﬂa-
iviruses
. Mathengtheng ∗, F.J. Burt
UNIVERSITY OF THE FREE STATE, 9324, ZA, South Africa
Background: Crimean Congo haemorrhagic fever (CCHF)
irus is widely distributed in Africa. Though cases of sus-
ected CCHF infections are routinely investigated, less than
0% are conﬁrmed. A proportion are usually Rickettsia spp.
nfections but a large number remain undiagnosed. This
arrants investigation of other tick-borne pathogens such
s ﬂaviviruses. Although the presence of mosquito-borne
aviviruses in southern Africa is known, that of tickborne
aviviruses was suggested by serological evidence in cat-
le but not conﬁrmed. Ixodes ticks are the known principal
ectors of tick-borne ﬂaviviruses and are endemic in south-
rn Africa. The domain III of the ﬂavivirus envelope protein
as reported to differentiate between the highly cross-
eactive tick- and mosquito-borne ﬂaviviruses. Our aim was
o prepare a noncross reactive representative tick-borne
ecombinant antigen that will differentiate between anti-
odies against the tick- and mosquito-borne members, and
o develop a nested multiplex PCR that can be used for
ifferentiation. Langat virus, a tick-borne ﬂavivirus, was
elected as representative for preparation of a recombinant
ntigen because it can be handled in a BSL 2 laboratory.
Methods: The domain III region of the envelope protein
EDIII) of Langat virus was ampliﬁed by PCR and cloned
nto a pQE-80L expression vector. The recombinant protein
as expressed in a bacterial expression system, puriﬁed
n Nickel-charged columns and characterized using Western
lot. The protein was evaluated in an ELISA for cross-
eactivity with mosquito-borne ﬂaviviruses. For the nested
ultiplex PCR, primers that amplify conserved regions of
aviviruses and CCHF were identiﬁed.
Results: The assay was nested to increase sensitivity
nd detected the viral nucleic acid of 10 known ﬂa-
iviruses and CCHF virus. A 13kDa EDIII recombinant protein
as expressed and puriﬁed. The antigen was able to dif-
erentiate between antibodies directed against tickand
osquito-borne ﬂaviviruses and also showed clear cut-offs
hen tested against known positive antibodies directed
gainst louping ill, tick-borne encephalitis and West Nile
iruses.
Conclusion: The recombinant antigen is an important tool
or the differentiation of ﬂaviviral groups and will be used
o screen human and cattle sera for antibody against tick-
orne ﬂavivirus. Similarly the multiplex PCR will be a useful
ool for screening acute serum samples and ticks.
oi:10.1016/j.ijid.2010.02.1594
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novel cell encapsulation mode for delivery of thera-
eutic antibodies against West Nile Virus infections that
aintains steady plasma antibody levels throughout ther-
py
.J.S. Chua1,∗, E.M. Brandtner2, J.A. Dangerﬁeld2, B.
almons2, W.H. Gunzburg2, M.L. Ng1
National University of Singapore, Singapore, Singapore
SGaustria, Singapore, Singapore
Background: West Nile virus (WNV) is currently endemic
n various parts of all ﬁve continents in the world. Being
member of the Japanese encephalitis virus subgenus,
NV can cause potentially fatal neuro-invasive diseases
uch as encephalitis and meningitis. Unfortunately, to date,
o vaccine or antiviral therapy has yet been approved.
ne antiviral strategy in development involves the pas-
ive administration of neutralizing antibodies. As with
ost immuno-therapies, plasma antibody levels diminish
etween treatments. This is especially detrimental in ﬂa-
ivirus immuno-therapies as sub-neutralizing concentrations
f antibodies can instead enhance infection. Here, we
eport a proof-of-concept for a novel mode of delivery
sing encapsulation of hybridoma cells producing therapeu-
ic antibodies which enables the maintenance of a steady
evel of antibody in the plasma, thus preventing any possible
ntibody-dependent enhancement (ADE).
Methods: Recombinant domain III of the envelope glyco-
rotein (rE-DIII) of WNV was cloned, expressed in bacteria,
nd puriﬁed. It was then inoculated into balb/c female mice
nd splenocytes harvested to generate hybridomas. Limit-
ng dilution was subsequently performed and producers of
ntibody speciﬁc to WNV were selected. Following which,
he selected hybridomas were encapsulated in polymers
f sodium cellulose sulfate. Viability of the encapsulated
ybridoma clones, their ability to continuously secrete anti-
odies, and most importantly, whether antibodies can be
eleased from the capsules were then characterized.
Results: Pilot batches of hybridomas remained viable and
ivided beyond 100 days postencapsulation. Moreover, the
ncapsulated hybridoma cells and their progeny were able
o continuously secrete WNV-speciﬁc antibodies, and the
ecreted antibodies could be released from the capsules.
Conclusion: Our preliminary results showed that encap-
ulation of cells producing therapeutic antibodies can
ndeed be a potential solution to improving treatment out-
omes for immunotherapies. This is especially essential
or immunotherapies against ﬂavivirus infections so as to
inimize any potential ADE side-effect. However, the appli-
ation of this technology for the treatment of infectious
iseases is still at its infancy and we are currently in the
idst of further optimizing and characterizing this technol-
gy.
oi:10.1016/j.ijid.2010.02.1595
